Published in Cancer Res on January 01, 1993
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol (1993) 2.85
Evaluating the pharmacokinetics and in vivo cancer targeting capability of Au nanocages by positron emission tomography imaging. ACS Nano (2012) 1.10
Radioluminescent gold nanocages with controlled radioactivity for real-time in vivo imaging. Nano Lett (2013) 1.09
Elucidation of the tumoritropic principle of hypericin. Br J Cancer (2005) 0.81
In vivo fluorescence kinetics and localisation of aluminum phthalocyanine disulphonate in an autologous tumour model. Br J Cancer (1996) 0.80
Three-dimensional miniature endoscopy. Nature (2006) 1.82
Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol (2001) 1.82
Targeted antimicrobial photochemotherapy. Antimicrob Agents Chemother (1998) 1.79
Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J Natl Cancer Inst (1999) 1.71
In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring. Br J Cancer (2009) 1.51
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin. Br J Cancer (1994) 1.43
Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol (1994) 1.42
Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc Natl Acad Sci U S A (1986) 1.36
Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology (1994) 1.27
Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology (1996) 1.25
Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol (1995) 1.24
Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis. Photochem Photobiol (1998) 1.21
Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. Cancer Res (2000) 1.20
Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res (2001) 1.18
Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res (1996) 1.17
Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br J Cancer (2006) 1.16
Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res (2001) 1.15
Photodynamic treatment of rheumatoid and inflammatory arthritis. Photochem Photobiol (1996) 1.13
Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res (1991) 1.12
Comparison of narrowband ultraviolet B exposure and oral vitamin D substitution on serum 25-hydroxyvitamin D concentration. Br J Dermatol (2012) 1.12
Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer (1998) 1.12
Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res (1998) 1.11
Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res (1997) 1.10
Targeted photodestruction of human colon cancer cells using charged 17.1A chlorin e6 immunoconjugates. Br J Cancer (2000) 1.08
Photoluminescence spectroscopy of carbon nanotube bundles: evidence for exciton energy transfer. Phys Rev Lett (2007) 1.07
BPD-MA-mediated photosensitization in vitro and in vivo: cellular adhesion and beta1 integrin expression in ovarian cancer cells. Br J Cancer (1999) 1.07
Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods (2001) 1.06
Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res (1996) 1.06
Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br J Dermatol (2010) 1.06
The effect of charge on cellular uptake and phototoxicity of polylysine chlorin(e6) conjugates. Photochem Photobiol (1997) 1.06
Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology (1994) 1.06
Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer (1996) 1.05
Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Photochem Photobiol (1996) 1.03
Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model. J Urol (1995) 1.03
Erythroderma: a follow-up of fifty cases. J Am Acad Dermatol (1983) 1.02
In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med (1995) 1.01
The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). J Photochem Photobiol B (1995) 1.00
Integrin-mediated adhesion and signalling in ovarian cancer cells. Cell Signal (1998) 1.00
Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br J Cancer (1994) 1.00
Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br J Cancer (2002) 0.99
Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol (2007) 0.99
Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br J Cancer (1997) 0.99
Phototoxicity of lumidoxycycline. J Invest Dermatol (1993) 0.98
Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. Phys Med Biol (2012) 0.98
In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res (1999) 0.97
Mechanisms of resistance to photodynamic therapy. Curr Med Chem (2011) 0.96
Pegylation of charged polymer-photosensitiser conjugates: effects on photodynamic efficacy. Br J Cancer (2003) 0.96
Rhodamine dyes as potential agents for photochemotherapy of cancer in human bladder carcinoma cells. Cancer Res (1989) 0.94
A multicenter study of patch test reactions with dental screening series. Am J Contact Dermat (2001) 0.94
Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer (1997) 0.94
Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer (1996) 0.94
Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus (2008) 0.93
Reverse phase high performance liquid chromatography of Escherichia coli ribosomal proteins: standardization of 70 S, 50 S, and 30 S protein chromatograms. J Biol Chem (1983) 0.93
Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol Oncol (2000) 0.92
Phototoxicity of the tetracyclines: photosensitized emission of singlet delta dioxygen. Proc Natl Acad Sci U S A (1986) 0.91
Absorbed photodynamic dose from pulsed versus continuous wave light examined with tissue-simulating dosimeters. Appl Opt (1997) 0.90
Tm-doped fiber laser mode-locked by graphene-polymer composite. Opt Express (2012) 0.90
Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer. Br J Cancer (2000) 0.90
In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour. Br J Cancer (1999) 0.90
Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents. Cancer Res (1992) 0.89
Mechanism of tetracycline phototoxicity. J Invest Dermatol (1984) 0.88
Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres. Proc Natl Acad Sci U S A (1991) 0.88
Structural considerations in the metabolism of nitriles to cyanide in vivo. Drug Metab Dispos (1983) 0.88
p53 expression and clinical outcome in prostate cancer. Br J Urol (1993) 0.88
Effects of photodynamic therapy with topical application of 5-aminolevulinic acid on normal skin of hairless guinea pigs. J Photochem Photobiol B (1992) 0.87
Photodynamic therapy of arteries. A novel approach for treatment of experimental intimal hyperplasia. Circulation (1992) 0.87
Accumulation of matrilysin (MMP-7) and macrophage metalloelastase (MMP-12) in actinic damage. J Invest Dermatol (1999) 0.86
Tunable Q-switched fiber laser based on saturable edge-state absorption in few-layer molybdenum disulfide (MoS₂). Opt Express (2014) 0.86
Vitamin D and prostate cancer. J Steroid Biochem Mol Biol (2001) 0.86
Hormonal modulation of the accumulation of 5-aminolevulinic acid-induced protoporphyrin and phototoxicity in prostate cancer cells. Int J Cancer (1997) 0.86
A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiat Res (1997) 0.86
Transient absorption changes in vivo during photodynamic therapy with pulsed-laser light. Br J Cancer (1999) 0.85
Mechanistic investigation of doxycycline photosensitization by picosecond-pulsed and continuous wave laser irradiation of cells in culture. J Biol Chem (1990) 0.85
Accounting for pharmacokinetic differences in dual-tracer receptor density imaging. Phys Med Biol (2014) 0.85
Reversed-phase high-performance liquid chromatographic separations of tetracycline derivatives using volatile mobile phases. J Chromatogr (1985) 0.85
Benzoporphyrin-lipoprotein-mediated photodestruction of intraocular tumors. Exp Eye Res (1996) 0.84
Photodynamic tissue adhesion with chlorin(e6) protein conjugates. Invest Ophthalmol Vis Sci (1999) 0.84
Narrowband ultraviolet B course improves vitamin D balance in women in winter. Br J Dermatol (2010) 0.83
Wideband saturable absorption in few-layer molybdenum diselenide (MoSe₂) for Q-switching Yb-, Er- and Tm-doped fiber lasers. Opt Express (2015) 0.83
A photobiological and photophysical-based study of phototoxicity of two chlorins. Cancer Res (2001) 0.83
Pharmacokinetics of a fluorescent drug using laser-induced fluorescence. Cancer Res (1993) 0.83
Photodynamic therapy inhibition of experimental intimal hyperplasia: acute and chronic effects. J Vasc Surg (1994) 0.83
Mid-infrared Raman-soliton continuum pumped by a nanotube-mode-locked sub-picosecond Tm-doped MOPFA. Opt Express (2013) 0.82
Reversed-phase high-performance liquid chromatography of Escherichia coli ribosomal proteins. Characteristics of the separation of a complex protein mixture. J Chromatogr (1983) 0.82
Comparison of intravenous and intravesical administration of chloro-aluminum sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model. J Urol (1992) 0.82
Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma. Photochem Photobiol (1998) 0.82
Targeted optical imaging and photodynamic therapy. Ernst Schering Res Found Workshop (2005) 0.81
[Selective occlusion of subretinal neovascularization with photodynamic therapy]. Ophthalmologe (1994) 0.80
Ultrastructure and dynamics of selective mitochondrial injury in carcinoma cells after doxycycline photosensitization in vitro. Am J Pathol (1988) 0.80
Rhodamine 123 phototoxicity in laser-irradiated MGH-U1 human carcinoma cells studied in vitro by electron microscopy and confocal laser scanning microscopy. Cancer Res (1990) 0.80
Protective effects of cadmium chloride against UVB injury in mouse skin and in cultured human cells: a possible role of cadmium-induced metallothionein. Photodermatol Photoimmunol Photomed (1991) 0.80
Matrix metalloproteinases as mediators of tissue injury in different forms of cutaneous lupus erythematosus. Br J Dermatol (2007) 0.79
Allergy to systemic and intralesional corticosteroids. Br J Dermatol (1993) 0.79
[Photodynamic therapy of experimental, intraocular tumors with benzoporphyrin-lipoprotein]. Ophthalmologe (1994) 0.79
Early events in ultraviolet light-induced skin lesions in lupus erythematosus: expression patterns of adhesion molecules ICAM-1, VCAM-1 and E-selectin. Acta Derm Venereol (1999) 0.78
Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate (2000) 0.78
Chloroaluminum sulfonated phthalocyanine partitioning in normal and intimal hyperplastic artery in the rat. Implications for photodynamic therapy. Am J Pathol (1993) 0.78
Cationic photoimmunoconjugates between monoclonal antibodies and hematoporphyrin: selective photodestruction of ovarian cancer cells. Appl Opt (1998) 0.78
Comparison of two routes of photosensitizer administration for photodynamic therapy of bladder cancer. Urol Res (1994) 0.77